Connective Tissue Matrix Compared to Steroid Injections for Rotator Cuff Tendinopathy (NCT06712290) | Clinical Trial Compass
WithdrawnNot Applicable
Connective Tissue Matrix Compared to Steroid Injections for Rotator Cuff Tendinopathy
Stopped: No participants met eligibility and the study was closed.
United States0Started 2024-11-25
Plain-language summary
The goal of the study is to see which is better at treating patients which rotator cuff tendinopathy (RCT): a single injection of Connective Tissue Matrix boost (CTM) or a steroid shot.
Patients will be randomized (like flipping a coin) to the treatment. Patients and researchers will be blinded (not know) what group the patients are in.
Patients will come back to the study clinic at 6 weeks, 3 months and 6 months after the shot to answer questionnaires, have a physical exam, and complete physical function tests to check their shoulder.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients aged 18-80 years old with rotator cuff tendinopathy
* A corticosteroid or CTM-type injection was determined by the clinician to be the proper medical treatment course and patient is willing to undergo the injection
Exclusion Criteria:
* Patients with adhesive capsulitis
* Patients with acromio-clavicular joint impingement, retracted tears, significant labral lesions or significant glenohumeral arthrosis
* Patients with joint instability
* History of shoulder surgery or corticosteroid injection in the past 3 months
* Patients with a history of chronic steroid treatment for any medical reason
* Patients with medical conditions that may affect healing, such as
* End-stage renal disease
* Uncontrolled diabetes
* Peripheral vascular disease
* Severe and/or systemic immunocompromising conditions such as Lupus or HIV infection
* Patients who are pregnant or breast feeding
What they're measuring
1
Raw WORC Score at 3 Month Visit
Timeframe: 3 Month Visit
Trial details
NCT IDNCT06712290
SponsorAllegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)